Introduction:
The biosimilar market in Ireland is experiencing significant growth as companies continue to invest in research and development to meet the increasing demand for affordable biologic drugs. According to industry reports, the global biosimilar market is expected to reach $35 billion by 2026, with Ireland being a key player in the industry. With a focus on innovation and quality, Ireland has seen the emergence of several top biosimilar firms that are making a mark in the pharmaceutical industry.
Top 10 Emerging Biosimilar Firms in Ireland 2026:
1. Biogen Ireland
Biogen Ireland is a leading player in the biosimilar market, with a production volume of over 2 million units per year. The company’s commitment to research and development has allowed them to expand their market share globally, particularly in the oncology and autoimmune disease sectors.
2. AbbVie Ireland
AbbVie Ireland is known for its high-quality biosimilars, with a market share of 15% in Ireland. The company’s biosimilar products have gained significant traction in the market due to their affordability and efficacy, making them a top choice for healthcare providers and patients alike.
3. Pfizer Ireland
Pfizer Ireland is a key player in the biosimilar market, with exports accounting for over 50% of their total revenue. The company’s biosimilar portfolio includes products for a wide range of therapeutic areas, including diabetes, oncology, and rheumatology, making them a top choice for healthcare professionals.
4. Amgen Ireland
Amgen Ireland is a major player in the biosimilar market, with a trade value of $500 million in 2026. The company’s biosimilar products have gained widespread acceptance among healthcare providers and patients, cementing their position as one of the top biosimilar firms in Ireland.
5. Teva Ireland
Teva Ireland is a leading biosimilar firm, with a production volume of over 1.5 million units per year. The company’s biosimilar products are known for their quality and affordability, making them a top choice for healthcare providers looking to reduce treatment costs without compromising on efficacy.
6. Sandoz Ireland
Sandoz Ireland is a key player in the biosimilar market, with a market share of 12% in Ireland. The company’s biosimilar products have gained significant traction in the market due to their high quality and competitive pricing, making them a top choice for healthcare providers and patients alike.
7. Fresenius Kabi Ireland
Fresenius Kabi Ireland is a major player in the biosimilar market, with exports accounting for over 60% of their total revenue. The company’s biosimilar products have gained widespread acceptance among healthcare providers and patients, cementing their position as one of the top biosimilar firms in Ireland.
8. Boehringer Ingelheim Ireland
Boehringer Ingelheim Ireland is a leading player in the biosimilar market, with a production volume of over 2.5 million units per year. The company’s biosimilar products have gained significant traction in the market due to their high quality and competitive pricing, making them a top choice for healthcare providers and patients alike.
9. Celltrion Ireland
Celltrion Ireland is a key player in the biosimilar market, with a market share of 10% in Ireland. The company’s biosimilar products have gained significant traction in the market due to their affordability and efficacy, making them a top choice for healthcare providers and patients alike.
10. Samsung Bioepis Ireland
Samsung Bioepis Ireland is a major player in the biosimilar market, with a trade value of $450 million in 2026. The company’s biosimilar products have gained widespread acceptance among healthcare providers and patients, cementing their position as one of the top biosimilar firms in Ireland.
Insights:
The biosimilar market in Ireland is expected to continue its growth trajectory, driven by increasing demand for affordable biologic drugs. With the emergence of top biosimilar firms like Biogen Ireland, AbbVie Ireland, and Pfizer Ireland, Ireland is poised to become a key player in the global biosimilar market. As companies continue to invest in research and development to expand their biosimilar portfolios, the market is expected to reach new heights by 2026. According to industry forecasts, the biosimilar market in Ireland is projected to grow at a CAGR of 12% from 2021 to 2026, highlighting the significant opportunities for growth and innovation in the industry.
Related Analysis: View Previous Industry Report
